PCVX · Vaxcyte, Inc.

NasdaqHealthcareBiotechnology

Vaxcyte Inc Is A Clinical-Stage Vaccine Company Engineering High-Fidelity Vaccines To Protect Humankind From The Consequences Of Bacterial Diseases. It Uses The Xpresscf Cell-Free Protein Synthesis Platform To Develop Potentially Superior And Novel Conjugate And Protein Vaccine Candidates For Adult And Pediatric Indications. The Company'S Product Pipeline Includes: Vax-31, Vax-24, And Vax-Xl Pcv Vaccine Candidates; Vax-A1, A Novel Group A Strep Vaccine; And Vax-Gi, A Novel Shigella Vaccine, Among Others, In Their Different Stages Of Development.

HealthcareNasdaqUS

$107.34

+86.4% latest move

Price & move as of the most recent catalyst (Oct 5) — not a live quote.

FLOAT

130.6M

FREE FLOAT %

88%

SHARES O/S

148.8M

MARKET CAP

$11.04B

EXCHANGE

Nasdaq

COUNTRY

PCVX Catalyst History

Regulatory and ClinicalPositive Topline ResultsOct 5, 2026 · 5:23am ET

PCVXVaxcyte, Inc.

Vaxcyte Announced Positive Topline Data from OPUS-1 Phase 3 Trial of VAX-31

The pivotal adult Phase 3 trial results for the 31-valent pneumococcal conjugate vaccine candidate were positive.

Be early on the next PCVX spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →